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Abstract
We hypothesized that endometrial carcinoma (EC) patients with a prior cancer diag-
nosis, after accounting for EC arising after tamoxifen‐treated prior breast carcinoma, 
are more likely to have an underlying genetic basis. We used information from a 
population‐based study to compare measured risk factors, tumor characteristics, sur-
vival, and known mismatch repair (MMR) pathogenic variant status for EC sub-
groups according to prior diagnosis of cancer (none, breast cancer tamoxifen‐treated 
or not, Lynch Syndrome (LS)‐associated cancer). Family history of any cancer was 
increased for EC cases with prior breast cancer, both tamoxifen treated (P = 0.005) 
and untreated (P = 0.01). EC cases with prior LS‐associated cancer more often re-
ported family history of LS‐associated cancer (P = 0.04) and breast cancer (P = 0.05). 
EC patients with a germline pathogenic MMR gene variant were more likely to re-
port a prior cancer than cases with a MMR proficient tumor (P = 0.0001), but more 
than half (54.5%) of MMR carriers reported no prior cancer. Women developing EC 
after tamoxifen treatment for breast cancer were significantly more likely to develop 
EC of malignant mixed mullerian tumor subtype (13.2% vs 2.6%, P = 1.3 × 10−6), 
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1 |  INTRODUCTION
Endometrial carcinoma (EC) is the fifth most common can-
cer in women in developed countries, accounting for 4.8% 
of new cancers and 2.1% of cancer deaths. The highest in-
cidence rates in 2012 were estimated to be 19.1 and 15.6 
per 100 000 in North America and Western Europe, respec-
tively,1,2 attributed to the greater overall prevalence of obesity 
and metabolic syndromes in these regions.3
Established nongenetic risk factors for EC include age 
and exposure to exogenous estrogens, or endogenous hy-
perestrogenic status associated with nulliparity, early age 
at menarche, late‐onset menopause and obesity.4 In addi-
tion, tamoxifen use for treatment of invasive breast cancer 
is associated with an increased risk of developing EC,5 with 
several reports indicating that EC arising after tamoxifen‐
treated breast cancer may have poorer prognostic features.6,7 
Genetic risk factors for EC have been supported by the fact 
that there is at least a twofold increased risk of EC among 
women with at least one first‐ or second‐degree relative with 
EC.12,13 Such genetic factors include high‐risk pathogenic 
variants in the DNA mismatch repair (MMR) genes causing 
Lynch Syndrome, and very rarely, germline loss‐of‐func-
tion variants in the PTEN tumor suppressor gene causing 
Cowden Syndrome.14 We have recently shown that carriage 
of a pathogenic variant in an MMR gene only partly accounts 
for risk of EC associated with reported family history,12 in-
dicating that additional genetic risk factors remain to be 
identified. It is clear that common genetic variants identified 
through large‐scale genomewide association studies and can-
didate gene studies also contribute to EC risk, with currently 
identified risk variants accounting for ~6.8% of the familial 
relative risk of EC, and modeling studies suggesting an upper 
estimate of 28% of familial relative risk may be due to com-
mon variants.15,16
There is evidence that individuals with moderate‐high‐
risk pathogenic variants in cancer predisposition genes are 
more likely to develop multiple cancers in their lifetime. The 
cumulative risk of metachronous colorectal carcinoma was 
reported to be up to 69% among carriers of pathogenic ger-
mline MMR gene variants.23 Members of Li Fraumeni fami-
lies (due to TP53 pathogenic variants) were shown to have a 
fivefold increased risk of developing a second primary cancer 
compared to the general population.24 Further, studies evalu-
ating BRCA1/2 pathogenic variant carriers have reported that 
women with a first diagnosis of breast carcinoma had a sig-
nificantly higher risk of developing a pathologically similar 
contralateral breast carcinoma25 or ovarian carcinoma com-
pared to noncarriers.26
We thus hypothesized that report of a prior cancer, after 
accounting for EC arising after tamoxifen‐treated prior breast 
carcinoma, might identify women with EC more likely to 
have an underlying genetic basis. We anticipated that EC 
patients with a prior cancer diagnosis might be more likely 
to report a family history of cancer than EC cases with no 
prior cancer diagnosis. In addition, we considered the possi-
bility that classical epidemiological risk factors for EC (such 
as obesity) may be less important for EC patients with prior 
cancer report (and suspected genetic basis). To investigate 
these questions, we detailed prior cancer report and tamox-
ifen use for women with EC and controls participating in the 
population‐based Australian National Endometrial Cancer 
Study (ANECS). We compared epidemiological risk factors, 
reported family history, tumor characteristics, survival, and 
known MMR gene pathogenic variant status for EC sub-
groups according to cancer types diagnosed prior to recruit-
ment, and for women without EC and no reported personal 
history of cancer.
2 |  METHODS
2.1 | Study sample sets
All ANECS participants provided informed written consent, 
and approval was obtained from the QIMR Berghofer Medical 
Research Institute Human Research Ethics Committee, par-
ticipating hospitals and cancer registries. Details of partici-
pant ascertainment, eligibility criteria, questionnaires, and 
present with stage IV disease (8.8% vs 1.2%, P = 1.6 × 10−6), and have poorer sur-
vival (HRadj 1.96; P = 0.001). While report of prior cancer is an indicator of MMR 
pathogenic variant status, molecular analysis of all ECs at diagnosis is warranted to 
detect all patients with LS. Results also indicate the importance of longer‐term moni-
toring of women treated with tamoxifen for symptoms of EC, and the need for studies 
assessing the biological mechanism underlying the poorer prognosis of this subset of 
EC patients.
K E Y W O R D S
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data collection, including blood samples for genetic testing, 
and assessment of family history have been previously re-
ported.12,27 Clinicopathological data including histological 
subtype, grade, tumor stage, and lymphovascular space inva-
sion (LVSI) were abstracted from medical/pathology records. 
Cases were re‐staged using the International Federation of 
Gynecology and Obstetrics (FIGO) 2009 criteria. Following 
convention regarding grading of “non‐endometrioid” tumors, 
and knowledge of prognostic features of tumors of mixed 
histology,28 tumor histology and grade were combined in a 
single variable with the following categories: endometrioid 
grade 1, endometrioid grade 2, endometrioid grade 3, serous 
(≥5%), clear cell (≥10%, and no serous ≥5%), carcinosar-
coma (malignant mixed mullerian tumor, MMMT), and other 
epithelial. Vital status was determined from medical records 
and using probabilistic record data linkage to the Australian 
National Death Index. Survival time was calculated from 
date of primary treatment for EC to date of death (overall, 
EC‐specific) or censored at 31 December 2013.
The dataset used for this analysis was based on informa-
tion for 1399 EC cases and 740 controls who were eligible to 
participate. Information about report of prior cancer was ex-
tracted from questionnaires (cases and controls), and supple-
mented by information from medical reports ascertained by 
clinical follow‐up studies, and from information about prior 
cancer noted in endometrial cancer pathology reports (cases 
only). Tamoxifen use for individuals with prior breast cancer 
was verified where possible from breast or EC pathology re-
ports, and/or from clinical records.
The detailed breakdown of all prior cancers in controls 
and EC cases is reported in Table S1. After in‐depth reviews 
from all available data sources, we identified 86 controls 
and 184 EC cases with a prior cancer diagnosis. The most 
commonly reported prior cancer diagnosis was breast can-
cer; 41 controls and 101 EC cases (97 self‐reported and four 
identified from medical records). Among the 101 EC cases 
with prior breast cancer, 68 had been treated with tamoxi-
fen (47 self‐reported, and another 21 identified from clinical 
follow‐up studies or pathology reports), and 33 self‐reported 
no tamoxifen use with no contradictory information from all 
available clinical records.
We also analyzed a subset of EC cases with at least one 
diagnosis of a cancer type falling into the Lynch Syndrome 
(LS) spectrum (termed LS‐associated) prior to EC diagnosis. 
Cancers considered to be LS‐associated included cancer of 
the bile duct, bladder, brain, colon/rectum, duodenum, endo-
metrium, gastrointestinal tract, ovary, pancreas, renal pelvis, 
and stomach. Of 15 women self‐reporting prior ovarian can-
cer, only two were determined to be true prior cancers, based 
on age at diagnosis and information from clinical follow‐up 
or pathology reports; for 11 women, their ovarian cancer di-
agnosis was actually concurrent with EC, and EC pathology 
reports for another two women indicated that their ovaries 
were normal and intact at hysterectomy for EC. For the pur-
poses of this analysis, women who had ovarian cancer that 
was concurrent with EC were included among those with no 
prior cancer unless they had been diagnosed with another 
cancer prior to their EC diagnosis. A total of 27 EC cases had 
been diagnosed with at least one prior LS‐associated cancer.
In addition to breast and LS‐associated cancers, there were 
68 EC patients and 38 controls with reports of other cancer 
types, with some individuals reporting multiple prior cancer 
types (Table S1). The remaining 1215 EC patients and 653 
controls reported no prior cancer at enrollment in ANECS. 
An additional control had insufficient data to determine her 
prior cancer status.
2.2 | Statistical analysis
The risk of EC associated with known epidemiologic risk 
factors was evaluated using age‐adjusted logistic regression 
models. Using controls reporting no prior cancer at inter-
view (n = 653) as reference, risk estimates were evaluated 
for: (a) cases with no history of cancer prior to EC diagnosis 
(n = 1215); (b) cases diagnosed with breast cancer prior to 
EC who were treated with tamoxifen (n = 68); (c) cases diag-
nosed with breast cancer prior to EC with no known tamox-
ifen use (n = 33); and (d) cases who had been diagnosed with 
at least one LS‐associated cancer prior to EC (n = 27). Age 
(at diagnosis for women with EC, at enrolment for controls) 
was entered into regression models as a continuous variable. 
Body mass index (BMI) was analyzed as a categorical vari-
able comparing women with a BMI 25‐29, and ≥30 to those 
with BMI <25 kg/m2. Parity, defined as the number of preg-
nancies ≥6 months, was analyzed as 1 or ≥2 vs 0. Age at 
menarche was analyzed as 12‐13 or ≥14 vs ≤11. Risk fac-
tors for EC, for example, oral contraceptive use, smoking, 
and ≥3 months use of systemic menopausal hormone therapy 
(postmenopausal women only) were entered into models as 
ever vs never use. We also evaluated all patient subgroups for 
EC risk associated with family cancer history comparing any 
vs no first‐ or second‐degree relative (FDR or SDR) report-
ing any invasive cancer, any LS cancer, and breast or ovarian 
cancer. For patient characteristics analyzed as ordinal vari-
ables, we assessed the trend across ordered groups using the 
nonparametric Cuzick’s test for trend.
We used Cox regression models to evaluate overall and 
EC‐specific survival of cases with a prior breast cancer di-
agnosis and tamoxifen use, prior breast cancer and no known 
tamoxifen use, and cases diagnosed with at least one LS‐asso-
ciated cancer prior to EC, compared to those with no history 
of cancer prior to EC diagnosis. Cox models were adjusted 
for the following: age at EC diagnosis as a continuous vari-
able; tumor stage in three categories (FIGO stages I, II, and 
III & IV); tumor histology in seven categories (endometrioid 
Grade 1, 2, or 3, serous, clear cell, carcinosarcoma/MMMT, 
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other epithelial); presence/absence of LVSI. Survival time 
was defined as the interval from date of first treatment for EC 
to date of death from any cause or due to EC, or censored at 
31 December 2013.
In addition, we evaluated the relationship between prior 
cancer and tumor/germline MMR status as previously de-
termined27 for 722 of the 1399 cases included in this study; 
558 were classified as IHC proficient and did not undergo 
germline genetic testing on the assumption they were very 
unlikely to carry a pathogenic MMR gene variant, 142 were 
IHC deficient with no pathogenic variant identified by germ-
line DNA testing, and 22 were IHC deficient and carriers of a 
pathogenic MMR gene variant. Differences in the frequency 
of IHC proficient and deficient tumors were evaluated for pa-
tients with prior breast cancer according to tamoxifen treat-
ment, and patients with prior LS‐associated cancer compared 
to patients with no prior cancer.
T A B L E  1  Association of epidemiological risk factors with endometrial cancer risk, according to report of prior breast or lynch  
syndrome cancer
Characteristicsa
Controls with 
no prior cancer 
(n = 653) Patients with no prior Cancer (n = 1215)
Patients with prior breast cancer &  
tamoxifen use (n = 68) Patients with prior breast cancer and no tamoxifen use (n = 33) Patients with prior LS‐associated cancers (n = 27)
Nb (%) Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd
Age (years)
Mean age (SD) 60.6 (9.9) 60.9 (9.4) 0.5 66.8 (8.3) <0.0001 66.0 (7.4) 0.002 62.1 (10.0) 0.4
Age Range 31.5‐80.1 26.4‐80.0 47.0‐78.7 51.2‐78.4 33.3‐78.4
<50 94 (14.4) 142 (11.7) 3 (4.4) 0 (0.0) 2 (7.4)
≥ 50 559 (85.6) 1073 (88.3) 65 (95.6) 33 (100.0) 25 (92.6)
BMI
<25 315 (49.5) 295 (24.4) 1.00 23 (33.8) 1.00 12 (36.4) 1.00 7 (25.9) 1.00
25‐29.9 189 (29.7) 296 (24.5) 1.65 (1.29‐2.10) 5.58E−05 25 (36.8) 1.63 (0.89‐3.00) 0.05 9 (27.3) 1.14 (0.47‐2.78) 0.77 10 (37.0) 2.32 (0.87‐6.21) 0.09
≥30 133 (20.9) 617 (51.1) 4.96 (3.88‐6.35) 2.12E−37 20 (29.4) 2.24 (1.17‐4.29) 0.02 12 (36.4) 2.47 (1.07‐5.70) 0.03 10 (37.0) 3.38 (1.26‐9.07) 0.02
Test for Trend 1.14E−39 0.01 0.06 0.01
OC use
Never 106 (16.3) 381 (31.4) 1.00 27 (39.7) 1.00 14 (42.4) 1.00 10 (37.0) 1.00
Ever 546 (83.7) 833 (68.6) 0.41 (0.32‐0.53) 1.92E−12 41 (60.3) 0.45 (0.25‐0.81) 0.008 19 (57.6) 0.36 (0.16‐0.78) 0.01 17 (63.0) 0.33 (0.14‐0.78) 0.01
Parity
0 46 (7.0) 217 (17.9) 1.00 9 (13.2) 1.00 6 (18.2) 1.00 3 (11.1) 1.00
1 59 (9.0) 119 (9.8) 0.42 (0.27‐0.66) 1.39E−04 8 (11.8) 0.69 (0.24‐2.01) 0.5 4 (12.1) 0.51 (0.13‐1.97) 0.33 4 (14.8) 1.02 (0.22‐4.78) 0.98
≥2 548 879 (72.3) 0.32 (0.23‐0.45) 7.52E−11 51 (75.0) 0.40 (0.18‐0.90) 0.03 23 (69.7) 0.26 (0.10‐0.69) 0.01 20 (74.1) 0.51 (0.15‐1.82) 0.30
Test for Trend 1.36E−10 0.05 0.03 0.18
Smoking
Never 384 (58.9) 785 (64.6) 1.00 44 (64.7) 1.00 25 (78.1) 1.00 20 (74.1) 1.00
Ever 268 (41.1) 430 (35.4) 0.79 (0.65‐0.96) 0.02 24 (35.3) 0.95 (0.56‐1.63) 0.86 7 (21.9) 0.46 (0.20‐1.09) 0.08 7 (25.9) 0.52 (0.21‐1.25) 0.14
Age at menarche
≤11 96 (15.9) 269 (22.3) 1.00 18 (26.5) 1.00 4 (12.5) 1.00 7 (25.9) 1.00
12‐13 328 (50.9) 584 (48.5) 0.64 (0.49‐0.83) 0.001 30 (44.1) 0.50 (0.26‐0.96) 0.04 19 (59.4) 1.44 (0.47‐4.37) 0.52 10 (37.0) 0.42 (0.15‐1.13) 0.09
14+ 221 (34.3) 352 (29.2) 0.57 (0.42‐0.75) 1.04E−04 20 (29.4) 0.47 (0.23‐0.93) 0.03 9 (28.1) 0.99 (0.29‐3.31) 0.98 9 (33.3) 0.56 (0.20‐1.54) 0.26
Test for Trend 0.0002 0.08 0.70 0.47
Hormone use in postmenopausal women
Never 298 (57.6) 643 (67.4) 1.00 45 (69.2) 1.00 20 (60.6) 1.00 14 (60.9) 1.00
Ever 219 (42.4) 311 (32.6) 0.66 (0.53‐0.82) 1.91E−04 20 (30.8) 0.62 (0.36‐1.09) 0.10 13 (39.4) 0.89 (0.43‐1.83) 0.75 9 (39.1) 0.88 (0.37‐2.06) 0.76
aAge at diagnosis for patients, at interview for controls; SD, standard deviation; BMI, body mass index; OC, oral contraceptive use. 
bNs may not sum to the total because of missing or unknown data; proportions (%) sum to 100% of observations where data available and excludes missing/unknowns. 
cRisk estimates (Odds Ratios and 95% confidence intervals) are adjusted for age as a continuous variable (at diagnosis for patients, at interview for controls). 
dP‐values for Mean age variables represent pairwise comparisons of means between Controls no prior cancer and Case subgroups. 
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All tests for association were two‐tailed, and performed 
using STATA SE v. 13 (Stata Corp., USA), and the R project for 
Statistical Computing version 3.2.2 (http://www.r-project.org/).
3 |  RESULTS
As detailed in Table S1, there was no indication that report of 
prior cancer was elevated in patients compared to controls, 
overall (13.2% vs 11.8%, P = 0.4), or considering individ-
ual cancer types. The proportion with reported tamoxifen‐
treated breast cancer was nonsignificantly higher in cases 
compared to controls (3.4% vs 2.8% based on self‐reported 
data only, P = 0.5; additional exploration of tamoxifen 
usage for cases only (from pathology reports or clinical fol-
low‐up) increased the proportion of tamoxifen‐treated prior 
breast cancer among cases to 4.9%). There was no difference 
between cases and controls for report of prior LS‐associated 
T A B L E  1  Association of epidemiological risk factors with endometrial cancer risk, according to report of prior breast or lynch  
syndrome cancer
Characteristicsa
Controls with 
no prior cancer 
(n = 653) Patients with no prior Cancer (n = 1215)
Patients with prior breast cancer &  
tamoxifen use (n = 68) Patients with prior breast cancer and no tamoxifen use (n = 33) Patients with prior LS‐associated cancers (n = 27)
Nb (%) Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd Nb (%) ORc (95% CI) Pd
Age (years)
Mean age (SD) 60.6 (9.9) 60.9 (9.4) 0.5 66.8 (8.3) <0.0001 66.0 (7.4) 0.002 62.1 (10.0) 0.4
Age Range 31.5‐80.1 26.4‐80.0 47.0‐78.7 51.2‐78.4 33.3‐78.4
<50 94 (14.4) 142 (11.7) 3 (4.4) 0 (0.0) 2 (7.4)
≥ 50 559 (85.6) 1073 (88.3) 65 (95.6) 33 (100.0) 25 (92.6)
BMI
<25 315 (49.5) 295 (24.4) 1.00 23 (33.8) 1.00 12 (36.4) 1.00 7 (25.9) 1.00
25‐29.9 189 (29.7) 296 (24.5) 1.65 (1.29‐2.10) 5.58E−05 25 (36.8) 1.63 (0.89‐3.00) 0.05 9 (27.3) 1.14 (0.47‐2.78) 0.77 10 (37.0) 2.32 (0.87‐6.21) 0.09
≥30 133 (20.9) 617 (51.1) 4.96 (3.88‐6.35) 2.12E−37 20 (29.4) 2.24 (1.17‐4.29) 0.02 12 (36.4) 2.47 (1.07‐5.70) 0.03 10 (37.0) 3.38 (1.26‐9.07) 0.02
Test for Trend 1.14E−39 0.01 0.06 0.01
OC use
Never 106 (16.3) 381 (31.4) 1.00 27 (39.7) 1.00 14 (42.4) 1.00 10 (37.0) 1.00
Ever 546 (83.7) 833 (68.6) 0.41 (0.32‐0.53) 1.92E−12 41 (60.3) 0.45 (0.25‐0.81) 0.008 19 (57.6) 0.36 (0.16‐0.78) 0.01 17 (63.0) 0.33 (0.14‐0.78) 0.01
Parity
0 46 (7.0) 217 (17.9) 1.00 9 (13.2) 1.00 6 (18.2) 1.00 3 (11.1) 1.00
1 59 (9.0) 119 (9.8) 0.42 (0.27‐0.66) 1.39E−04 8 (11.8) 0.69 (0.24‐2.01) 0.5 4 (12.1) 0.51 (0.13‐1.97) 0.33 4 (14.8) 1.02 (0.22‐4.78) 0.98
≥2 548 879 (72.3) 0.32 (0.23‐0.45) 7.52E−11 51 (75.0) 0.40 (0.18‐0.90) 0.03 23 (69.7) 0.26 (0.10‐0.69) 0.01 20 (74.1) 0.51 (0.15‐1.82) 0.30
Test for Trend 1.36E−10 0.05 0.03 0.18
Smoking
Never 384 (58.9) 785 (64.6) 1.00 44 (64.7) 1.00 25 (78.1) 1.00 20 (74.1) 1.00
Ever 268 (41.1) 430 (35.4) 0.79 (0.65‐0.96) 0.02 24 (35.3) 0.95 (0.56‐1.63) 0.86 7 (21.9) 0.46 (0.20‐1.09) 0.08 7 (25.9) 0.52 (0.21‐1.25) 0.14
Age at menarche
≤11 96 (15.9) 269 (22.3) 1.00 18 (26.5) 1.00 4 (12.5) 1.00 7 (25.9) 1.00
12‐13 328 (50.9) 584 (48.5) 0.64 (0.49‐0.83) 0.001 30 (44.1) 0.50 (0.26‐0.96) 0.04 19 (59.4) 1.44 (0.47‐4.37) 0.52 10 (37.0) 0.42 (0.15‐1.13) 0.09
14+ 221 (34.3) 352 (29.2) 0.57 (0.42‐0.75) 1.04E−04 20 (29.4) 0.47 (0.23‐0.93) 0.03 9 (28.1) 0.99 (0.29‐3.31) 0.98 9 (33.3) 0.56 (0.20‐1.54) 0.26
Test for Trend 0.0002 0.08 0.70 0.47
Hormone use in postmenopausal women
Never 298 (57.6) 643 (67.4) 1.00 45 (69.2) 1.00 20 (60.6) 1.00 14 (60.9) 1.00
Ever 219 (42.4) 311 (32.6) 0.66 (0.53‐0.82) 1.91E−04 20 (30.8) 0.62 (0.36‐1.09) 0.10 13 (39.4) 0.89 (0.43‐1.83) 0.75 9 (39.1) 0.88 (0.37‐2.06) 0.76
aAge at diagnosis for patients, at interview for controls; SD, standard deviation; BMI, body mass index; OC, oral contraceptive use. 
bNs may not sum to the total because of missing or unknown data; proportions (%) sum to 100% of observations where data available and excludes missing/unknowns. 
cRisk estimates (Odds Ratios and 95% confidence intervals) are adjusted for age as a continuous variable (at diagnosis for patients, at interview for controls). 
dP‐values for Mean age variables represent pairwise comparisons of means between Controls no prior cancer and Case subgroups. 
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cancers overall (1.9% vs 2.0%). There was some suggestion 
that cases were more likely to report two or more prior can-
cer types compared to controls (1.5% vs 0.7%), but this dif-
ference was not statistically significant (P = 0.1).
3.1 | Association with epidemiological 
risk factors
Results are detailed in Table 1. Comparison of age at en-
dometrial cancer diagnosis in patient subgroups shows that 
patients with prior breast cancer were diagnosed with EC at 
somewhat older age than those with no prior cancer (mean 
age 67 and 66 years among tamoxifen users and nonusers, 
respectively, vs 61 years among those with no prior cancers; 
P ≤ 0.002). There was no evidence that endometrial cancer 
was diagnosed at an earlier age for patients with prior LS‐as-
sociated cancers (62 years, P = 0.4).
Endometrial carcinoma risk in women with no cancer 
prior to EC diagnosis was associated with known epidemi-
ologic risk factors for this disease.4 Compared to controls 
with no prior history of cancer, BMI ≥ 30 was associated 
with an almost fivefold increased risk of EC for women with 
no prior cancer history. There was a highly significant trend 
in increased risk associated with BMI categories of ≥25 
to <30 and ≥30 (P = 1.4 × 10−39). Oral contraceptive use, 
older age at menarche, parity, and use of systemic hormone 
therapy (mostly combination therapy in postmenopausal 
women) were inversely associated with EC risk in women 
with no prior cancers (P ≤ 0.001), and there was a signifi-
cant trend toward a lower risk of EC associated with older 
age at menarche (P = 0.0002) and higher numbers of full‐
term births (P = 1.4 × 10−10; Table 1). In addition, there 
was evidence to support the previously reported inverse 
association of EC risk with smoking (P = 0.02). The risk 
estimates for EC following a prior breast or LS‐associated 
cancer associated with the risk factors highlighted above 
were necessarily imprecise given the smaller sample sizes. 
Nevertheless, they were generally in the same direction as 
those reported for EC with no prior cancer, with elevated 
risk associated with increasing BMI, and decreased risk 
associated with OC use, increasing parity, later age at men-
arche, and postmenopausal HRT use. Possible exceptions 
were ever‐smoking, which did not appear to be inversely 
associated with EC among women with prior breast cancer 
and tamoxifen use, while age at menarche did not appear to 
be inversely associated with EC among women with prior 
breast cancer and no tamoxifen use.
3.2 | Association with reported family 
history of cancer
As shown in Table 2, women with no prior cancer had a 
43% increased risk of EC if at least one FDR or SDR was 
reported to have any cancer diagnosis (P = 2.5 × 10−4) or 
any LS cancer (P = 2.7 × 10−4), but no significant increased 
EC risk associated with having an FDR or SDR with breast 
cancer (P = 0.3) or ovarian cancer (P = 0.9). Despite small 
sample sizes, there was marginal evidence that women with 
prior breast cancer had increased risk of EC if they reported 
a family history of cancer in close relatives, be that family 
history of any cancer type (OR 2.23, P = 0.005 for tamox-
ifen users; OR 2.80, P = 0.01 for nonusers), family history 
of breast cancer (OR 1.98, P = 0.01 for tamoxifen users; OR 
1.95, P = 0.07 for nonusers), or family history of LS‐asso-
ciated cancers (OR 1.78, P = 0.03 for tamoxifen users). All 
cases with prior LS‐associated cancer reported a family his-
tory of cancer, and for this subgroup, there was evidence for 
increased risk associated with reported family history of LS‐
associated cancer (OR 2.34, P = 0.04) or family history of 
breast cancer (OR 2.15, P = 0.05).
T A B L E  4  Overall and EC‐specific survival in patients reporting a prior cancer
Patient subgroup
Overall survivala EC‐specific survivalb
N Died (%) HRc (95% CI) P N Died (%) HRc (95% CI) P
Patients with no prior cancer 
(n = 1215)
153 (12.6) 1.00 104 (8.6) 1.00
Patients with prior breast cancer 
and tamoxifen use (n = 68)
23 (33.8) 1.96 (1.24‐3.11) 0.004 17 (25.0) 1.91 (1.11‐3.29) 0.02
Patients with prior breast cancer 
and no tamoxifen use (n = 33)
7 (21.2) 1.14 (0.46‐2.78) 0.8 4 (5.9) 1.33 (0.49‐3.64) 0.6
Patients with prior LS‐associated 
cancers (n = 27)
3 (11.1) 0.72 (0.23‐2.28) 0.6 1 (1.5) 0.33 (0.05‐2.39) 0.3
aSurvival time estimated from date of primary treatment for EC to date of death from any cause censored. 
bSurvival time estimated from date of primary treatment for EC to date of death due to EC. 
cEffect estimates are based on Cox models adjusted for age at EC diagnosis, FIGO stage, tumor subtype, and LVSI. 
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3.3 | Differences in EC tumor pathology 
prognostic variables and survival according to 
prior cancer
Cases with prior breast cancer (irrespective of tamoxifen treat-
ment) or prior LS‐associated cancer were less likely to present 
with a grade 1 or 2 endometrioid adenocarcinoma than the ref-
erence group of EC cases with no prior cancer (Table 3). In 
particular, women with tamoxifen‐treated breast cancer were 
significantly more likely to develop an endometrial carcinosar-
coma (MMMT; 13.2% vs 2.6%, P = 1.3 × 10−6), and present 
with stage IV disease (8.8% vs 1.2%, P = 1.6 × 10−6). In ac-
cordance with this observation, women with tamoxifen‐treated 
breast cancer had poorer overall survival (HRadj 1.96; P = 0.001) 
and EC‐specific survival (HRadj 1.91; P = 0.02) compared to 
women with no prior cancer. Women with prior breast cancer 
and no tamoxifen use or prior LS‐associated cancer exhibited 
similar survival to those with no prior cancer (P ≥ 0.27; Table 
4 & Figure S1). The minimum follow‐up time was 7.8 years 
post‐treatment.
3.4 | Differences in EC tumor and germline 
MMR status
The relationship between MMR status and prior cancer is 
summarized in Table 5. EC patients with a proven germline 
pathogenic MMR gene variant were significantly more likely 
to report a prior cancer than cases whose cancers were MMR 
proficient (45.5% vs 14.3%, P = 0.0001). Prior cancers 
reported by pathogenic MMR gene variant carriers included 
breast cancer with tamoxifen use (9.1% vs 6.1% in the ref-
erence group, P = 0.6), prior LS‐associated cancer (18% vs 
2%, P < 0.0001), and other prior cancer (18.2% vs 4.7%, 
P = 0.005). Patients with MMR tumor deficiency but no 
MMR germline pathogenic variant identified were slightly 
more likely to report no prior cancer compared to the refer-
ence group of MMR proficient cases, but this difference was 
not statistically significant (91.5% vs 85.7%, P = 0.07).
4 |  DISCUSSION
We hypothesized that there may be a genetic contribution 
to EC risk in patients reporting prior cancer, after account-
ing for tamoxifen treatment for prior breast cancer. Our 
baseline comparison of reported prior cancer in controls 
compared to EC cases supported the known association 
between tamoxifen treatment for breast cancer and subse-
quent risk of EC. There was no evidence to suggest that 
any reported prior cancer, reported breast cancer without 
tamoxifen treatment, or LS‐associated cancers combined, 
was more common for cases compared to controls, con-
firming that reported prior cancer alone is not useful as a 
generic feature to identify women at increased risk of sus-
pected familial EC.
Recognizing that sample sizes for the subgroups of women 
with prior cancer were small, our results nonetheless suggest 
that epidemiological factors conferring increased risk of EC 
T A B L E  5  MMR status according to patient prior cancers
Patient subset with 
IHC data
MMR proficienta 
n = 558
MMR deficient (no pathogenic 
variant)b n = 142
P†
MMR deficient (pathogenic 
variant carrier)c n = 22
P†N (%) N (%) N (%)
No prior cancer 478 (85.7) 130 (91.5) 0.07 12 (54.5) 0.0001
Prior breast cancer with 
tamoxifen use
34 (6.1) 5 (3.5) 0.20 2 (9.1) 0.60
Prior breast cancer—no 
tamoxifen use
11 (2.0) 2 (1.4) 0.60 0 (0.0) na
Prior Lynch cancer 11 (2.0) 2 (1.4) 0.60 4 (18.2) <0.0001
Patients with dother 
prior cancer
26 (4.7) 4 (2.8) 0.30 4 (18.2) 0.005
aMismatch repair (MMR) proficient patients (n = 558) were proficient in immunohistochemistry testing for EC tumor expression of MLH1, MSH6 and PMS2, and were 
not tested for gene sequence changes ‐ assumed to have no pathogenic variant. 
bMMR deficient patients (n = 142) were deficient in immunohistochemistry for at least one of MLH1, MSH2, MSH6, or PMS2, and genetic testing identified no patho-
genic or likely pathogenic variant. MMR deficiency was confirmed (somatic MLH1 methylation) or assumed to be due to somatic causes. 
cMMR deficient pathogenic variant carriers were deficient in immunohistochemistry for at least one of MLH1, MSH2, MSH6, or PMS2, and genetic testing identified of 
a pathogenic MMR variant consistent with pattern of IHC loss. 
dOther Prior Cancers among MMR proficient were melanoma (n = 18), thyroid (n = 2), cervix (n = 1), larynx (n = 1), other unspecified (n = 4); among MMR deficient 
no pathogenic variant were melanoma (n = 3) and thyroid (n = 1); among MMR‐deficient pathogenic mutation carriers were melanoma (n = 2), cervix (n = 1), and 
thyroid (n = 1). 
†P‐values are derived from chi‐squared comparison of proportions between MMR deficient and proficient cases. 
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have similar directions of effect for EC cases with no prior 
cancer compared to those with prior breast cancer or LS‐as-
sociated cancer. We considered explanations for the possible 
exceptions to anticipated associations with epidemiological 
risk factors for women with prior cancer, noting that in all 
instances the relevant risk estimates included unity. Smoking 
is thought to reduce circulating endogenous estrogen and so 
result in a reduced risk of EC, as observed for EC after prior 
LS‐associated cancer or prior breast cancer in the absence of 
tamoxifen use. The observation that smoking was not asso-
ciated with EC among women with prior breast cancer and 
tamoxifen use might be explained by the fact that exposure 
to tamoxifen and not endogenous estrogen is the major mech-
anism for risk in this subset of women. There is no obvious 
explanation for the observation that women with prior breast 
cancer and no tamoxifen use did not show an inverse associ-
ation with increasing age at menarche, especially since this 
subgroup of women did show a statistically significant in-
verse EC risk associated with increasing parity. It thus seems 
reasonable to discount the observation as spurious, reflecting 
the small sample size for this group.
All subgroups of individuals with prior cancer showed 
an increased proportion of reported family history of cancer 
(FDR and/or SDR) compared to EC cases with no prior can-
cer or controls with no prior cancer, even those with tamox-
ifen‐treated breast cancer (Table 2). EC risk associated with 
reported family history of breast cancer did not differ accord-
ing to tamoxifen usage for prior breast cancer (OR 1.98 for 
prior breast cancer with tamoxifen use vs OR 1.95 for prior 
breast cancer no tamoxifen use). Interestingly, for patients 
with prior LS‐associated cancer, the elevation in EC risk for 
reported family history of LS‐associated cancer (OR 2.34; 
95% CI 1.05‐5.09) was similar to that for reported family his-
tory of breast cancer (OR 2.15; 95% CI 0.99‐4.69). These ob-
servations are consistent with the expectation that individuals 
with genetic factors underlying their disease might present 
with prior cancer and/or family history of cancer. Indeed, all 
patients with a prior LS‐associated cancer reported a family 
history of cancer, and the cancer type in relative/s was des-
ignated as LS‐associated for 17/27 (63%) of these patients 
(Table 2).
Report of prior LS‐associated cancer is considered an in-
dicator of MMR pathogenic variant carrier status.29 Patients 
identified as carriers of a pathogenic MMR gene variant were 
overall more likely to report a prior cancer. Recognizing that 
these observations were based on a small sample set of 22 
carriers, it was surprising to note that less than half of the 
prior cancers reported (4/10 total) were LS‐associated can-
cers, with the remainder comprising tamoxifen‐treated breast 
carcinoma (n = 2), melanoma (n = 2), and cervical and 
thyroid carcinomas. Nonetheless, when considering MMR 
status within groups defined by prior cancer, 4/17 (23.5%) 
individuals with prior LS‐associated cancer were identified 
to be a pathogenic variant carrier, compared to 12/620 (1.9%) 
of individuals with no prior cancer. This observation empha-
sizes that diagnosis of a first primary LS‐associated cancer 
is an important clinical indicator to prioritize MMR gene 
testing and could enable timely identification of MMR gene 
pathogenic variant carriers for implementation of appropri-
ate cancer risk reduction strategies to prevent second pri-
mary cancers. However, it is also important to note that more 
than half (54.5%) of MMR pathogenic variant carriers did 
not report any prior cancer, indicating that history of prior 
LS‐associated cancer alone has poor sensitivity to delineate 
patients with EC due to a germline MMR gene defect.
Although tamoxifen has clearly been shown to be ben-
eficial for treatment of breast cancer,30,31 it is associated 
with a two‐ to threefold increased risk of EC compared to 
age‐matched women in the general population.5,8,32 There 
is evidence that this subgroup of EC patients are enriched 
for poor‐prognosis pathological features and/or have poor 
survival,6 of interest since tamoxifen users might be ex-
pected to be under greater scrutiny for symptoms of EC. 
A brief review summarizing the main findings of selected 
studies is presented in Table S2. As detailed in Table 3, our 
findings support previous reports that EC after tamoxifen 
use for breast cancer has adverse prognostic features. In our 
study, the proportion of MMMTs after tamoxifen treatment 
for breast cancer was increased (13% vs <3% in cases with 
no prior cancer), equating to a 5.6‐fold increase. Patients 
were more likely to present with stage IV EC after tamox-
ifen treatment for breast cancer (9% vs 3% for tamoxifen 
nonusers). Interestingly, these correlations appear to be in-
dependent; only two of the nine individuals with MMMT 
(22.2%) were Stage IV and another 3 (33.3%) were stage 
III. Our study did not collect information on duration of 
tamoxifen use, so we were not able to assess if MMMT 
are more likely to arise after long‐term tamoxifen use (as 
previously reported). Compared to EC patients with no 
prior cancer, women diagnosed with EC after tamoxifen‐
treated breast cancer had significantly worse survival out-
comes (HR 1.96; P = 0.004 any cause, HR 1.91; P = 0.02 
EC‐specific). In stark contrast, there was no evidence for a 
survival difference for women reporting prior breast cancer 
without tamoxifen treatment or prior LS‐associated cancers 
(P ≥ 0.3). Notably, although women with prior tamoxifen‐
treated breast cancer had a higher prevalence of MMMT 
tumors compared to those with prior breast cancer and no 
tamoxifen use, this survival difference was not totally ac-
counted for by poorer prognostic features of EC subtypes 
(Table 4).
A limitation of our study was that information on prior 
cancers was based on patient self‐report, although where 
possible these were confirmed using data from clinical 
follow‐up, and pathology reports. Information appeared to 
be reasonably accurate with the exception of self‐reported 
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prior ovarian cancer, most of which were determined to be 
concurrent with EC. ANECS participants had to have an 
intact uterus at the time of EC diagnosis to participate, so 
it is not surprising that there were so few prior ovarian can-
cers among EC cases since standard surgical management 
for ovarian carcinoma, which accounts for the great major-
ity of ovarian cancers, includes hysterectomy. Clinical fol-
low‐up was undertaken for cases but not controls, allowing 
us to verify self‐reported data for EC cases only. Since we 
restricted the reference group to controls with no prior can-
cer for case‐control analysis, failure to identify over‐report 
of prior cancers in this group (estimated to be only 2/740 
controls based on observations for cases) would have min-
imally biased our overall results toward the null. Further, 
any bias in data quality should not have impacted case‐case 
analysis.
This study has confirmed the relationship between EC 
risk and prior tamoxifen‐treated breast cancer, and also pre-
vious reports that tamoxifen‐treated breast cancers are more 
likely to lead to poorer prognosis EC. However, consider-
ing all possible sources of information regarding tamox-
ifen treatment, we also estimate that one‐third of all EC 
after breast cancer did not appear to be tamoxifen related. 
Epidemiological risk factors were largely similar across 
subgroups according to prior cancer report. Supporting 
our hypothesis that cancer‐causing genetic factors will be 
enriched in individuals with prior cancer, a family history 
of cancer was increased for all patient subgroups reporting 
prior cancer. Surprisingly, this included family history of 
LS‐associated cancers for EC cases with tamoxifen‐treated 
prior breast cancer, and family history of breast cancer for 
individuals with prior LS‐associated cancer. Further, while 
prior LS‐associated cancer is clearly an indicator of MMR 
pathogenic variant status, so is report of other prior cancer 
types. However, 55% of established carriers did not report 
prior cancer, supporting the increasingly accepted role of 
universal immunohistochemical or molecular analysis of 
all ECs at diagnosis to detect patients with LS.
An important finding arising from this study is that 
women developing EC after tamoxifen treatment for breast 
cancer exhibited poorer survival—even after adjustment 
for known EC‐related prognostic features. We suggest that 
it is important to ensure longer‐term monitoring of women 
treated with tamoxifen for symptoms of EC. We also be-
lieve there is scope for studies assessing the biological 
mechanism underlying the poorer prognosis of this subset 
of EC patients.
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